United Therapeutics forward PE UTHR

Share price divided by analysts' consensus earnings for the next twelve months, since 2004.

Today, Oct 23, 2026: 22.0×
10-year median: 10.7×
Against its 10-year history: 100th; percentile: 0 is its lowest day, 100 its highest
10-year range: 7.2× to 22.0×
Peer median: 37.4×

United Therapeutics' forward PE is 22.0× as of Oct 23, 2026.

That is above its ten-year median of 10.7×, higher than on 100% of days in the last ten years.

Over that time it ranged from 7.2× in Jul 2019 to 22.0× in Oct 2026.

The median for 10 biotech stocks of a similar size is 37.4×.

Forward PE over time

median 10.7×

The dashed line is the 10-year median and the shaded band the middle half of its days.

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	22.0×	17.1×	22.0×
2025	18.6×	9.9×	19.0×
2024	13.0×	9.0×	14.8×
2023	9.6×	9.5×	14.5×
2022	14.7×	10.1×	14.8×
2021	13.9×	12.0×	15.7×
2020	12.1×	7.4×	12.1×
2019	8.1×	7.2×	12.2×
2018	9.6×	7.4×	11.1×
2017	9.8×	7.7×	12.2×
2016	10.4×	8.0×	11.2×
2015	12.4×	9.4×	16.2×
2014	12.6×	8.3×	12.8×
2013	10.7×	7.5×	10.7×
2012	8.7×	7.7×	11.7×
2011	11.0×	9.2×	28.1×
2010	26.1×	21.3×	39.2×
2009	34.4×	10.7×	42.1×
2008	10.5×	8.5×	40.4×
2007	38.8×	23.0×	49.0×

Against its peers

Companies in Biotechnology nearest United Therapeutics' size, closest first, today.

Company	Forward PE
UTHRUnited Therapeutics	22.0×
INCYIncyte	49.5×
ALNYAlnylam Pharmaceuticals	26.7×
EXELExelixis	n/m
ONCBeOne Medicines	48.1×
NBIXNeurocrine Biosciences	n/m
HALOHalozyme Therapeutics	n/m
TECHBIO-TECHNE	n/m
RGENRepligen	n/m
KRYSKrystal Biotech	n/m
REGNRegeneron Pharmaceuticals	12.6×
Peer median	37.4×

Where United Therapeutics ranks

#32of 51Healthcare stocks with the lowest forward PE

What the forward PE tells you

Price divided by what analysts expect the company to earn over the next twelve months. It answers "what am I paying for next year" instead of last year.

Estimates are opinions. When forward PE is far below trailing PE, analysts expect a big jump in earnings. If that jump slips, the stock was not as cheap as it looked.

More on United Therapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.